← ILMN: big moves and long-term fundamentals中文

Illumina: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 12, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and the Q3 2026 release

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 2026 release.

Illumina makes DNA-sequencing machines and, mostly, the chemicals and kits they use: every sample run needs new consumables, so most revenue repeats. In fiscal 2025 revenue was $4.34B, flat on 2024; it reports one segment, Core Illumina, after spinning off the cancer-test company GRAIL in June 2024 (10-K, notes 2 and 12).

2025 (disclosed) Revenue Share of total
Consumables / instruments / service and other $3.23B / $0.48B / $0.63B 74% / 11% / 15%
Sequencing / microarrays (chips that test many known DNA markers at once) $3.99B / $0.36B 92% / 8%
Americas (US: $2.24B) / Europe / Greater China / Asia-Pacific, Middle East and Africa $2.41B / $1.26B / $0.24B / $0.43B 55% / 29% / 6% / 10%
  • No customer accounted for more than 10% of consolidated revenue in 2023–2025 (10-K, note 1).
  • Clinical labs drive growth; research customers have been cutting back. In Q3 2026, sales of supplies to clinical customers outside Greater China rose 14% while research and applied fell 6% (prepared remarks).
  • Shares percentages are our calculation1.

2. Story so far

Last updated Oct 30, 2026. Reflects filings and releases through Oct 29, 2026.

In short: Illumina’s 2021 purchase of GRAIL, closed while European regulators were still reviewing it, led to a prohibition, a fine, about $6.6B of write-downs and a change of chief executive before GRAIL was spun off in 2024. Since then the filings show flat revenue, a return to profit in 2025 and large buybacks, while China put Illumina on its unreliable-entities list. In 2026 Illumina raised its forecast three times.

Date Milestone Source
Aug 18, 2021 ★ Completes the GRAIL acquisition for $9.7B, including $2.9B cash, a contingent value right (a right to future payments tied to GRAIL revenue) and 10M shares from treasury, while the EU review is pending 10-K FY2021; equity statement
Sep 6, 2022 European Commission prohibits the deal 10-K FY2023
FY2022 $3.9B GRAIL goodwill and intangible impairment; net loss $4.4B 10-K FY2023
Jun 11, 2023 CEO Francis deSouza resigns 8-K
Jul 12, 2023 EU fines Illumina €432M, 10% of its 2022 revenue, for closing early 10-K FY2023
Sep 25, 2023 Jacob Thaysen becomes CEO 8-K
Jun 24, 2024 ★ Spins off GRAIL to shareholders, keeping about 14.5% 10-K FY2025, note 8
Sep 3–6, 2024 EU Court of Justice rejects the Commission’s jurisdiction; the Commission withdraws its decisions on Sep 6, and Illumina records a $489M operating-expense gain 10-K FY2024
Feb 4, 2025 ★ China adds Illumina to its List of Unreliable Entities and on Mar 4, 2025 bans exports of its sequencers into China; by Feb 5, 2026 the ban had been lifted, but purchases still need approval 10-K FY2025, risk factors; Q4 2025 release
FY2025 Net income $850M, including $328M of gains mainly on the GRAIL stake; buybacks $742M 10-K FY2025
Jan 30, 2026 Buys SomaLogic (protein measurement) for $460M 10-Q Q2 2026
Oct 28, 2026 US adds MGI Tech, BGI’s sequencer maker and an Illumina rival, to the Uyghur Forced Labor Prevention Act Entity List, restricting imports of its goods Federal Register; Reuters
Oct 29, 2026 ★ Q3 results: 2026 revenue guide raised to $4.64–4.66B, up from $4.5–4.6B in February; Investing.com reported an after-hours price of $255.88, down 11.8% from the $290.06 regular-session close. Start of our coverage: Why Illumina stock fell Q3 release; Q4 2025 release

3. Latest quarter: did the story change?

Last updated Nov 12, 2026. Reflects Q3 2026 (release Oct 29, 2026; 10-Q filed Oct 30, 2026) against Q2 2026.

Bottom line: According to its Oct 29 release, Illumina raised its 2026 revenue and earnings guidance for the third time this year, but revenue growth slowed to 4.2% in Q3 from 9.5% in Q2, and research customers kept cutting back.

Driver Last quarter → this quarter Management: before → now Signal
Revenue Q2 $1,159M (+9.5%) → Q3 $1,129M (+4.2%); $1,166M excluding tariff refunds 2026 guide $4.60–4.64B (Jul 30) → $4.64–4.66B (Oct 29) Better
Organic revenue growth outside Greater China (excluding currency and acquisitions; Q3 also excludes tariff refunds) Q2 8.1% → Q3 4.7% More than 5% for 2026 (Jul 30) → more than 5% (Oct 29) Worse
Adjusted diluted earnings per share (EPS; company measure; Q3 excludes tariff refunds) Q2 $1.31 → Q3 $1.44 2026 guide $5.30–5.40 (Jul 30) → $5.40–5.45 (Oct 29) Better
Greater China Q2 $56M → Q3 $59M; Q3 +13% year over year, or 7% organic No China guide → no China guide Better
Tariff refunds None → Q3 $79M benefit to costs and $37M reduction to revenue for credits to customers Excluded from guidance (Oct 29) Watch

Sources: Q2 2026 release, Q3 2026 release, Q3 presentation, Q3 revenue supplement.

Unresolved questions: whether research spending stabilises, as management said it was starting to; and how the refunds are finally settled.

4. Buybacks vs real dilution (5 years)

Last updated Nov 12, 2026. Reflects the equity statements in the 10-Ks for FY2021, FY2023 and FY2025 and the 10-Q Q3 2026, and Forms 4 filed to Nov 10, 2026.

Dilution in one line: shares outstanding rose about 4.8% from Jan 3, 2021 to Dec 28, 2025, about 0.9% a year compounded. If you owned 1% of Illumina at the start of 2021, you’d own about 0.95% at the end of 2025 without buying more2. Buybacks offset about half of the new shares. Our scale: Low (under 1% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Jan 3, 2021 to Dec 28, 2025FY2021 +7.5%, FY2022 +0.6%, FY2023 +0.6%, FY2024 0.0%, FY2025 −3.8%. Total +4.8% since Jan 3, 2021.−5%0%+5%+10%FY2021: +7.5% in the period; +7.5% since Jan 3, 2021+7.5%FY2021FY2022: +0.6% in the period; +8.2% since Jan 3, 2021+0.6%FY2022FY2023: +0.6% in the period; +8.9% since Jan 3, 2021+0.6%FY2023FY2024: 0.0% in the period; +8.9% since Jan 3, 20210.0%FY2024FY2025: −3.8% in the period; +4.8% since Jan 3, 2021−3.8%FY2025+4.8%since Jan 3, 2021

Change in the period Total since Jan 3, 2021

Shares outstanding at period end (all classes): 146.0M on Jan 3, 2021, 153.0M on Dec 28, 2025, +4.8% (our calculation). A bar below zero means the count fell (net buybacks).

Shares outstanding (one class of common stock; treasury shares excluded).

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 28, 2025)153.0M−3.8%$742M$275M6%
FY2024 (Dec 29, 2024)159.0M0.0%$116M$370M8%
FY2023 (Dec 31, 2023)159.0M+0.6%$0$380M8%
FY2022 (Jan 1, 2023)158.0M+0.6%$0$366M8%
FY2021 (Jan 2, 2022)157.0M+7.5%$0$754M17%
FY2020 (Jan 3, 2021)146.0M—$736M$194M6%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

Most new shares came from the GRAIL purchase and employee stock plans; buybacks resumed in 2024 after none in 2021–2023. Illumina reports share counts rounded to the nearest million.

Bridge (millions of shares) Shares
Start (Jan 3, 2021) 146
+ Newly issued shares, mainly employee plans, plus about 0.7M on settlement of convertible notes in 2021 (shares issued rose from 195M to 201M) +6
+ Shares from treasury for the GRAIL purchase (2021) +10
− Shares taken into treasury in 2021 with employee issuance ($91M) −1
− Buybacks (2024–2025; $864M) −8.7
End (Dec 28, 2025) 153
  • Components don’t sum exactly because the filings round to whole millions; the cover-page counts, given to 0.1M, show the same rise: 145.9M (Feb 12, 2021) to 152.9M (Feb 6, 2026)2.
  • Buybacks of 8.7M shares against about 16M new shares offset about half3.
  • At Oct 23, 2026, 151.2M shares were outstanding, after more buybacks in 2026 (10-Q, cover).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 — — — — — — 10-K FY2021 cash flow statement (no repurchase line)
2022 — — — — — — 10-K FY2023
2023 — — — — — — 10-K FY2023
2024 0.90M $128.32 (our calculation) $116M — — — 10-K FY2025, note 6
2025 7.79M $96.02 (our calculation) $748M — — — 10-K FY2025, note 6 (cash paid: $742M)
2026 to date (Jan–Sep) 2.99M $125.25 (our calculation) $375M — — — 10-Q Q3 2026, note 6 (Q3: 47,000 shares for $9M)

Illumina has sold no shares for cash in the period and bought back 11.7M shares for $1.24B since 2024; most were bought in 2025 at an average of about $96. Averages are our calculation4.

Basis and details
  • Illumina has had no stock split in the period. “Spent” is the cost of shares repurchased as reported, including commissions and excise taxes; buybacks exclude shares withheld for employee taxes.
  • Excluded from “sold for cash”: the 10M treasury shares used for GRAIL (2021), and employee plans.
  • Authorisations left at Sep 27, 2026: $270M under the 2024 programme and $1.5B under the 2026 programme (10-Q).
  • For reference, Nasdaq reports a $290.06 close on Oct 29, 2026, before the after-hours drop (Nasdaq).
Stock-based pay 2021 2022 2023 2024 2025 9M 2026
$M 941 366 380 371 275 207
% of revenue (our calculation)5 21% 8% 8% 8% 6% 6%

Total stock-based compensation expense fell about 71% from 2021 to 2025; 2021 included awards accelerated as part of the GRAIL deal (10-K FY2021; 10-K FY2025, note 6).

Insider transactions: Form 4 filings show net selling in the 12 months to Nov 10, 2026, almost all by investment funds linked to a director.

  • Funds advised by Corvex Management, reported on Form 4 filings by Illumina director Keith Meister, sold about 3.3M shares for about $658M between May and November 2026, including 281,433 shares for about $66.6M on Nov 3–4, after the Q3 results (our calculation from the filings’ weighted-average prices)6. Meister disclaims beneficial ownership except his financial interest.
  • Executives sold about 11,700 shares (about $1.7M); director Scott Gottlieb bought 200 shares (Feb 9, 2026).
  • Some executive sales were made under prearranged Rule 10b5-1 trading plans, including the chief people officer’s 2,370-share sale on Feb 18, 2026 and the chief legal officer’s 1,336-share sale on Feb 20, 2026 (Form 4; Form 4).
Insider details
  • Largest executive sales: the chief legal officer, chief people officer, strategy head and chief accounting officer (3,504; 3,937; 2,282 and 2,000 shares). Other entries are award grants, option exercises and shares withheld for taxes.
  • Illumina itself filed a Form 4 as a GRAIL shareholder: it sold 1.0M GRAIL shares at $79.85 on Nov 17, 2025 (Form 4).
  • We read all 68 Form 4 filings made by or on behalf of Illumina insiders from Oct 30, 2025 to Oct 29, 2026, and the 5 filed from Oct 30 to Nov 10, 2026: the Corvex sale above and four executives’ shares withheld for taxes on Nov 5 (filings list).
  • Scott Davies, the chief legal officer, has left the company; he ended his Rule 10b5-1 trading plan on Aug 14, 2026 in connection with his departure (10-Q).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the Q3 2026 release and the 10-Q Q3 2026. TTM = the four quarters to Sep 27, 2026 (our calculation)7.

Illumina turns more of its sales into cash than into reported profit. Large non-cash items in recent years were write-downs and the GRAIL stake’s gains and losses; in 2025, reported profit was lifted by $328M of investment gains that brought in no operating cash.

$M FY2025 TTM to Sep 27, 2026 (our calculation)
Net income 850 895
Non-GAAP net income (profit adjusted by the company to exclude specified items)8 756 Not calculated
Non-GAAP diluted EPS (company measure) $4.84 Not calculated
Operating cash flow 1,079 1,230
Capital spending −148 −173
Free cash flow (company definition)9 931 1,057

Helps future profit or cash:

  • Tariff refunds: Illumina booked a $79M benefit to costs in Q3 2026 for refunds it expects to recover. By Sep 27 it had received $32M and recorded a $47M receivable; it also recorded a $37M liability for credits it expects to pass on to customers (10-Q).
  • Stock-based compensation expense fell to $275M in 2025 from $371M in 2024; future share issuance also depends on award terms, vesting and performance.

Hurts future profit or cash:

  • Receivables rose and used $108M of cash in 2025: sales recorded but not yet collected.
  • Part of the refunds goes back to customers: Illumina cut Q3 revenue by $37M for credits it expects to give them.

One-off / no lasting effect:

  • Gains on strategic investments, mainly the GRAIL stake: +$328M in 2025, a $312M loss in 2024; they move net income but not operating cash.
  • Write-downs: $23M in 2025 after $1.9B in 2024 (GRAIL) and $3.9B in 2022.
  • 2024’s $489M gain from the withdrawn EU fine, and gains on the GRAIL contingent value rights ($315M in 2024), lowered expenses without cash.
The raw reconciling items (FY2025)

From the cash flow statement (10-K): depreciation $203M; amortisation of intangible assets $67M; stock-based pay $275M; deferred income taxes +$119M; net gains on strategic investments −$328M; change in contingent consideration −$18M; impairments $27M; non-cash charitable contribution $19M; working capital: receivables −$108M, inventory −$17M, other assets and lease items −$63M, other liabilities +$35M; other non-cash adjustments +$18M.

Self-funding

Funding: how long without new money? Self-funding: $1,057M of free cash flow in the 12 months to Sep 27, 2026; $500M of notes due in December 2027, against $1.34B of cash and short-term investments10.

Funding details
  • As of Sep 27, 2026: cash and cash equivalents $1,289M and short-term investments $48M; term debt $1,789M, none due within a year (Q3 release).
  • In August, Illumina sold $300M of 4.95% notes due 2029 and used them, with cash, to repay $500M of notes due Sep 9, 2026 (8-K, Aug 17).
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • A $1.0B unsecured revolving credit facility (a reusable borrowing line), signed Aug 13, 2026 and maturing Aug 13, 2031, had no borrowings or letters of credit outstanding at Sep 27, 2026. It is intended to back the commercial paper programme set up on Oct 8, 2026, which permits up to $1.0B of unsecured short-term borrowing, so the two are not separate $1B cushions (8-K; 8-K; 10-Q).

Shortens the runway:

  • $500M of 5.750% notes due Dec 13, 2027; then $300M (2029), $500M (Dec 12, 2030) and $500M (Mar 23, 2031) (10-K, note 5; 8-K).
  • Buybacks are discretionary: $1.77B of authorisations remained at Sep 27, 2026 (10-Q).

Conditional:

  • Completed, not a future cost: Illumina paid $30M on Jul 27, 2026 to extinguish the remaining SomaLogic contingent payments, before the Sep 27 balance sheet. Still conditional: the GRAIL contingent value rights, with a $36M fair value at Sep 27, 2026, linked to future GRAIL revenue (10-Q). Also conditional: through December 2026, Illumina must reimburse GRAIL for cash payments earned under a revenue-linked employee award with a maximum potential value of $78M; the recorded non-contingent liability was $1M at Sep 27, 2026 (10-Q).

6. Customer and contract exposure

Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q Q3 2026 and reports through Oct 29, 2026.

No customer accounts for more than 10% of revenue, but geography and politics matter: China has restricted Illumina since 2025, and the US has now restricted imports from its main Chinese rival.

Revenue by region, 2025 ($M)
Americas: $2,406MAmericas$2,406MEurope: $1,264MEurope$1,264MAsia-Pacific, Middle East, Africa: $430MAsia-Pacific, Middle East, Af…$430MGreater China: $243MGreater China$243M
Show the data
Label Value Unit
Americas 2406 $M
Europe 1264 $M
Asia-Pacific, Middle East, Africa 430 $M
Greater China 243 $M

Chart source11.

Customer and contract details
  • Customers: no customer accounted for more than 10% of consolidated revenue in 2023–2025 (10-K, note 1).
  • China: added to the List of Unreliable Entities on Feb 4, 2025; barred from exporting sequencers into China from Mar 4, 2025. Greater China revenue fell from $384M (2023) to $243M (2025) (10-K). By Feb 5, 2026, China had lifted the export ban, but Illumina remains on the list, so instrument purchases need approvals (Q4 2025 release).
  • MGI listing: on Oct 28, 2026 the Department of Homeland Security added MGI Tech, BGI Genomics and BGI Group to the UFLPA Entity List; US Customs presumes their goods are made with forced labour and blocks imports unless that is rebutted (Federal Register; Reuters). MGI denies the allegations and says its US business is limited (Reuters). No source we found quantifies the effect on Illumina. Matt Marlowe, a former BGI employee who writes the BridgeCross Bio newsletter, called significant new Chinese retaliation against the sector “relatively unlikely” (BridgeCross Bio).
  • US research funding: Illumina cites reductions in US National Institutes of Health funding as a headwind for research customers (10-Q).
  • GRAIL: Illumina sold the rest of its GRAIL shares in 2026, for $206M in total, so it no longer holds GRAIL stock; the contingent value rights to GRAIL revenue remain (section 5) (10-Q).

7. Illumina’s strategy for long-term growth

Last updated Oct 30, 2026. Reflects the 10-Ks for FY2021–FY2025, the 10-Q for Q2 2026, the Q3 2026 release and call, and attributed reports.

Illumina’s core business, sequencing kits for its own machines, faces expiring patents, lower prices as customers move to its newer NovaSeq X, weaker research budgets, restrictions in China and new rivals, including Roche. Its attempt to grow by owning GRAIL, a customer developing cancer tests, ended in a court-tested divestment and about $6.6B of write-downs. Since 2023, Chief Executive Jacob Thaysen has bet on clinical labs, multiomics (measuring more than DNA, such as proteins) and data and software, with targets for 2027 that the company says it is on track to meet.

Pressure on the core sequencing business

Illumina’s patents and its price per sample are both under pressure, and its research customers are spending less.

  • Illumina’s issued patents expire between 2026 and 2050; it warns that as patents on its sequencing-by-synthesis (SBS) chemistry expire, rivals can develop competing products (10-K, risk factors). In 2022, Illumina said one of its key SBS patents (the ’444) would expire in June 2023, GenomeWeb reported (GenomeWeb).
  • Prices: customers moving to the NovaSeq X pay less per sample. The CFO said these price headwinds should be smaller in 2027 than in 2026; research customers have largely switched, and about 78% of clinical volume was on the X in Q3 (reported Q3 call transcript, Investing.com, Oct 29, 2026).
  • Volumes: research and applied supplies outside Greater China fell 6% in Q3 2026, and Illumina expects a mid-to-high single-digit decline for the year; it cites cuts in US National Institutes of Health funding (prepared remarks; 10-Q).
  • China: Greater China revenue fell from $384M in 2023 to $308M in 2024 and $243M in 2025 (China added Illumina to its unreliable-entities list in February 2025), then grew 13% in Q3 2026 (10-K; Q3 supplement).

Roche is the newest large rival. On Jun 29, 2026, it launched AXELIOS 1, the first instrument based on its sequencing by expansion (SBX) technology, for research use only. Roche says it gives same-day whole-genome results and reads of up to about 1,500 bases, using a reusable sensor chip with millions of nanopores; it gave no price. Roche positions it as a possible replacement for existing technologies in key research areas, and says it could be used “potentially” in clinical settings in the future. Roche Diagnostics CEO Matt Sause said it “combines high accuracy with unprecedented speed and scalability” (Roche release).

Other competitors
  • Element Biosciences (AVITI) and Ultima Genomics (UG 100) sell lower-cost short-read instruments; a Genetic Engineering & Biotechnology News analysis said Ultima’s pursuit of a sub-$100 genome caused price cutting across the industry (GEN).
  • PacBio sold its short-read sequencing technology to Illumina for $50M in cash, completed Jan 30, 2026, and now focuses on long-read sequencing (PacBio).
  • MGI Tech, BGI’s sequencer maker, was added to the US UFLPA Entity List on Oct 28, 2026, restricting imports of its goods (section 6).
  • Huatai Securities estimates Illumina’s share of the global sequencer market at about 70% and MGI’s at 7–10%, Asia Times reported (Asia Times).
  • On the Q3 call, Thaysen said: “I am not super concerned about what others are doing right now” (reported Q3 call transcript, Investing.com, Oct 29, 2026).

The GRAIL chapter: an attempt at vertical integration

Illumina bought GRAIL, which develops a blood test for many cancers and runs on Illumina sequencers, while US and EU regulators were still reviewing the deal; both moved against it, and Illumina gave it up in 2024.

  • Deal: completed Aug 18, 2021 for $9.7B, including $2.9B of cash; Illumina already owned part of GRAIL (10-K FY2021; 10-K FY2023).
  • US: the FTC filed a complaint on Mar 30, 2021, alleging the deal violated US antitrust law (section 7 of the Clayton Act). An administrative law judge ruled for Illumina on Sep 1, 2022; the full Commission reversed that on Mar 31, 2023 and ordered Illumina to divest GRAIL. (10-K FY2023).
  • Appeal: on Dec 15, 2023, the Fifth Circuit found the FTC had applied the wrong standard to Illumina’s “open offer” of supply terms to GRAIL’s rivals, vacated the order and sent that question back, and upheld the Commission’s decision in all other respects (10-K FY2023).
  • EU: the European Commission prohibited the deal on Sep 6, 2022, fined Illumina €432M on Jul 12, 2023 for completing it before clearance (the maximum, 10% of its 2022 revenue), and ordered a divestment on Oct 12, 2023 (10-K FY2023).
  • Exit: Illumina said on Dec 17, 2023 that it would divest GRAIL and spun it off on Jun 24, 2024, keeping about 14.5% (10-K FY2025).
  • Reversal: on Sep 3, 2024 the EU Court of Justice ruled the Commission had no jurisdiction over the deal; the fine was withdrawn (10-K FY2024).
  • Cost: GRAIL write-downs of $3.9B (2022), $0.8B (2023) and $1.9B (2024), about $6.6B in total (10-K FY2023; 10-K FY2025).

The strategy under Jacob Thaysen

Management’s plan, set out in August 2024, is to return to growth by selling more to clinical labs, adding multiomics products and building a software and data business.

  • Targets: on Aug 13, 2024, Illumina set a goal of high-single-digit revenue growth by 2027 and non-GAAP EPS growth of double digits to the teens from 2025 to 2027, BioSpace reported (BioSpace); its 10-K describes the goals as “a return to revenue growth and improved margin performance by the end of 2027” (10-K).
  • Clinical: Thaysen said “healthy clinical demand” drove Q3 results; clinical supplies outside Greater China grew 14%, and management expects mid-teens growth for 2026 (Q3 release; prepared remarks).
  • Multiomics: Thaysen said Illumina had brought out “a very, very significant multi-omics portfolio” over 18 months (reported Q3 call transcript, Investing.com, Oct 29, 2026).
  • Software and data: BioInsight, set up about a year ago, combines Illumina’s software and data businesses; its first data product, the Billion Cell Atlas, has AstraZeneca, Merck and Eli Lilly as partners (reported Q3 call transcript, Investing.com, Oct 29, 2026; Q4 2025 release).
  • China: Thaysen called China “a huge opportunity” after the return to growth; management did not describe a separate diversification plan on the call (reported Q3 call transcript, Investing.com, Oct 29, 2026).
SomaLogic, the proteomics acquisition
  • Closed Jan 30, 2026, for $460M: $382M in cash and contingent payments with an estimated fair value of $81M, less $3M for an existing relationship (10-Q).
  • Illumina paid a $25M milestone for 2025 performance in Q2 2026, then $30M on Jul 27, 2026 to buy out the remaining contingent payments (10-Q).
  • Illumina also bought PacBio’s short-read technology for $50M on the same day (PacBio).

Is it working?

The filings and calls show progress on profit, slower progress on growth, and no disclosed figure for SomaLogic.

Strategy: what to watch

  • Roche’s AXELIOS 1: customer shipments, pricing and any clinical version.
  • SomaLogic: whether Illumina discloses its revenue as integration proceeds. BioInsight: the scale of its contribution in 2027; management already reported Billion Cell Atlas revenue in Q3 2026 (prepared remarks).
  • China: approvals still needed for instrument purchases, and any response to the US listing of MGI.
  • Patents and pricing: the size of NovaSeq X price headwinds in 2027.
  • 2027 guidance with Q4 results, against the high-single-digit growth target.

8. What to watch

Last updated Nov 12, 2026.

Date Item Source
Nov 2, 2026 Delaware court hearing on dismissing the settled Icahn shareholder suit over the GRAIL acquisition. Reported: Bloomberg Law said on Nov 3 that the court approved the settlement on Nov 2; the company filings cited disclosed only the scheduled hearing, and we have not seen the court order 8-K, Aug 7; Bloomberg Law, Nov 3
Dec 4, 2026 Defendants’ response due to the fourth amended complaint in the federal securities class action over the GRAIL deal; the court dismissed the third version on Sep 30 with leave to amend 10-Q, legal proceedings
With Q4 results (date not announced) 2027 guidance, which management said it plans to give then Investing.com transcript
Dec 13, 2027 $500M of 5.750% notes mature 10-K FY2025
Ongoing Any Chinese response to the US listing of MGI, given Illumina’s place on China’s unreliable-entities list BridgeCross Bio

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 30, 2026$235.99 (Oct 30)$35.6B$36.5B7.9×8.1×43.2×38.3×+5%21%($911M)12 months to Jun 28, 2026
Nov 12, 2026$212.93 (Nov 11)$32.2B$32.6B7.1×7.2×36.0×30.5×+6%23%($454M)12 months to Sep 27, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 27, 2026, filed Oct 30, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 30, 2026 row: Corrected Oct 31, 2026: cash and investments now exclude $88M of equity securities and non-marketable investments that Illumina reports within short-term investments; enterprise value and net debt updated. Price and date unchanged. Oct 30, 2026 price: official close, Nasdaq (Yahoo Finance daily history). Nov 12, 2026 price: Nasdaq historical close.

Notes and calculations

  1. Shares of 2025 revenue: $3,227M, $482M, $634M ÷ $4,343M; $3,985M and $358M ÷ $4,343M; $2,406M, $1,264M, $243M, $430M ÷ $4,343M (10-K, notes 2 and 12). ↩

  2. Balance-sheet counts (rounded): 146M at Jan 3, 2021 and 153M at Dec 28, 2025. Growth = 153 ÷ 146 − 1 ≈ 4.8%; annual rate = (153 ÷ 146)^(1 ÷ 5) − 1 ≈ 0.94%; remaining ownership = 1% × 146 ÷ 153 ≈ 0.95%. Cover-page check: 152.9M ÷ 145.9M − 1 = 4.8%. ↩ ↩2

  3. Buybacks 0.904M (2024) + 7.790M (2025) = 8.7M; new shares ≈ 6M newly issued (including about 0.7M on conversion of the 2021 notes) + 10M (GRAIL) = 16M; 8.7 ÷ 16 ≈ 54%. ↩

  4. Average price = cost ÷ shares: $116M ÷ 0.904M = $128.32; $748M ÷ 7.790M = $96.02; $375M ÷ 2.994M = $125.25. Total since 2024: 11.688M shares, $1,239M. ↩

  5. Total stock-based compensation expense ÷ revenue: $941M ÷ $4,526M; $366M ÷ $4,584M; $380M ÷ $4,504M; $371M ÷ $4,372M; $275M ÷ $4,343M; $207M ÷ $3,380M (9M 2026). ↩

  6. Sum of sale (code S) transactions in Corvex-reported Form 4 filings, May 2026 to Sep 4, 2026: 3,059,258 shares, ≈ $591M; plus Nov 3–4, 2026: 281,433 shares, ≈ $66.6M (13 sales at weighted-average prices of $225.12–$241.42; Form 4, Nov 2026); total 3,340,691 shares ≈ $657.7M; value = shares × each filing’s reported weighted-average price (e.g. Form 4, Sep 2026). Executive sales: 11,723 shares ≈ $1.73M. Transaction ledger (all 68 filings, Oct 30, 2025 to Oct 29, 2026): documents/gc-project-wmsm/fact-checks/ilmn-form4-ledger-2026-10-30.md. ↩

  7. FY2025 − first nine months of 2025 + first nine months of 2026. Net income: $850M − $516M + $561M = $895M. Operating cash flow: $1,079M − $758M + $909M = $1,230M. Capital spending: $148M − $93M + $118M = $173M (Q3 release). ↩

  8. Company reconciliation: $850M net income + $94M cost-of-revenue adjustments + $17M research and development (R&D) + $76M selling, general and administrative (SG&A) + $10M legal adjustments − $333M other-income adjustments + $42M tax adjustments = $756M (Q4 2025 release, table 2). ↩

  9. Operating cash flow − purchases of property and equipment: $1,079M − $148M = $931M (FY2025); $1,230M − $173M = $1,057M (TTM). ↩

  10. $1,289M + $48M = $1,337M at Sep 27, 2026. ↩

  11. 10-K FY2025, note 12, accessed Oct 30, 2026. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Illumina: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)